Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

European Biopharmaceutical Companies Launch Anticancer Drug Project

By BiotechDaily International staff writers
Posted on 12 Nov 2013
Two European biopharmaceutical companies are joining forces in an intensive effort to develop a new series of anticancer drugs.

ZoBio (Leiden, The Netherlands) will be applying its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target protein.

TINS is a powerful approach that has been validated on a wide range of targets including viral proteins, proteases, kinases, protein-protein interaction targets, molecular chaperones, and membrane proteins. TINS uses a single sample of the target and a reference protein that have been immobilized on Sepharose-based resin. Fragments to be assayed for binding are injected as mixtures of between three and nine compounds. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. Comparison of the NMR spectra of the fragments in the presence of the target and reference proteins directly reveals the identity of the binding ligand.

ZoBio offers its proprietary TINS technology for ligand screening studies on its own, highly validated fragment library or the customer’s. A typical TINS discovery and characterization/validation project is completed in one to two months.

ZoBio's partner in the new project is Actelion Ltd. (Allschwil, Switzerland), a company that has demonstrated global leadership in the field of pulmonary arterial hypertension (PAH) therapy. Actelion is known for a strong and effective worldwide specialty commercial organization, a highly productive discovery capability, and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

Dr. Gregg Siegal, CSO of ZoBio said, “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”

Related Links:

ZoBio
Actelion Ltd.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

Researchers Discover New Data on Protein Kinase A

By employing X-rays and neutron beams, a team of researchers have gleaned new information about protein kinase A (PKA), an omnipresent master control protein that helps regulate basic cellular functions such as energy consumption and interactions with neurotransmitters, hormones, and drugs. The scientists who conducted... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.